Evotec Signs License Agreement with MedImmune
The license gives MedImmune exclusive access to a portfolio of research programs and represents the first deal executed by Evotec on beta cell regeneration assets and capabilities.
The agreement triggers an upfront payment of E5m. Further on, additional deferred payments including potential milestone payments of up to E254m as well as royalties are agreed. The milestone payments will be due upon achievement of certain clinical as well as regulatory and commercial events.
Further milestone payments may be achieved with the approval of additional indications and programs. Evotec will also receive research payments to support further in vivo and in vitro pharmacology efforts conducted in collaboration with MedImmune.
Cord Dohrmann, chief scientific officer of Evotec, said: “The loss of insulin producing beta cells is tightly linked to the development of diabetes. Using a unique screening approach for beta cell regeneration targets, we have identified and validated novel and highly relevant biological factors. MedImmune is leader in biopharmaceutical research with cutting edge protein production and engineering capabilities and thus a perfect partner for Evotec.
“The most advanced factor has demonstrated efficacy in animal models of beta cell regeneration in particular increasing the functional beta cell mass and thereby improving and restoring glycemic control. Together we intend to generate a pipeline of biological factors that have the potential to prevent or reverse disease progression, and confer optimal glycemic control in patients.”
Will the deal benefit the firms in the diabetes therapeutic area?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.